Plasma is a key raw material of the
blood product industry. In August 2011, China shut down 16 plasma stations in
Guizhou, resulting in a decrease of 15% in the plasma volume of the year.
However, due to the implementation of favorable policies, widening gap between
supply and demand, rising product prices and other factors, more than 150
plasma stations in China produced about 3,600 tons of plasma in 2012, up 14.2%
year on year.
From 2012 to mid-2013, new plasma
stations of some Chinese enterprises have started plasma collection or obtained
plasma collection permits, such as Yuechi plasma station of Jiangxi Boya
Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and Caoxian plasma
station of China Biologic Products. It’s expected that China’s plasma supply
tension will be further eased after 2013.
To check out the Complete table of
contents, visit: http://www.marketresearchreports.biz/analysis-details/china-blood-product-industry-report-2012-2015
According to the lot release
statistics of National Institutes for Food and Drug Control, in the first ten
months of 2012, China’s total lot release volume of blood products was about
36.13 million bottles, an increase of 7.1% compared with the full year of 2011.
In addition, except human coagulation factor VIII with a decreased lot release
volume, other products saw growing release volume. In particular, human
immunoglobulin, tetanus immunoglobulin, human fibrinogen, imported human serum
albumin witnessed higher growth rates of 321%, 95%, 79%, 45% respectively in
the first ten months of 2012.
However, Chinese blood product
enterprises have weak R&D capability, low plasma utilization and fewer
product varieties. The domestic market is still dominated by technically
undemanding human serum albumin and human immunoglobulin (ph4) for intravenous
injection, which accounted for more than 60% of the lot release volume in
2012.
In order to ease the domestic
shortage of blood products, China has allowed the import of human serum albumin
and recombinant coagulation factor VIII in recent years. Human serum albumin
imports have grown rapidly due to low prices. The lot release volume was 8.51
million bottles in the first ten months of 2012, occupying 47.5% of the lot
release volume of such products (43.3% in 2011); Behring, Baxter, Instituto
Grifols and Octapharma were top four companies by lot release volume. However,
due to high prices and national policy restrictions, the import of recombinant
coagulation factor VIII is very small, only Bayer and Baxter products were
allowed to be imported as of the end of 2012.
To Buy The Copy of This Report
Visit: http://www.marketresearchreports.biz/analysis/170322
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
Blog: http://chinamarketreports.blogspot.com/
